Characterizing the clinical and economic burden of COVID-19 among individuals with immunocompromising conditions in Ontario, Canada – a matched, population-based observational study
IC experienced more severe COVID-19 hospitalization outcomes compared to non-IC. COVID-mitigating policies and prophylactic treatments are needed to protect immunocompromised populations.
Authors
- Austin Nam (ORCID: https://orcid.org/0000-0003-0714-8385)
- Karissa Johnston (ORCID: https://orcid.org/0000-0003-4570-9972)
- Christina Qian (ORCID: https://orcid.org/0000-0001-8297-8683)
- M. L. Voss (ORCID: https://orcid.org/0000-0002-7245-0778)
- Mackenzie A. Hamilton (ORCID: https://orcid.org/0000-0003-2423-3629)
- María Tinajero
Institutions
- AstraZeneca (Canada) (CA)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1080/13696998.2025.2482372
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.40